Dermata Therapeutics Inc（DRMA）股票分析DRMADermata Therapeutics Inc

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dermata Therapeutics is not a good buy right now. The current price is $0.78, and the stock has experienced a year-to-date change of -64.17%. Furthermore, the RSI is at 36.13, indicating it is nearing oversold territory but still lacks strong buying momentum. The company reported a net loss of $2.97 million in Q2 2026, which is a significant financial strain, and the cash reserves are dwindling, expected to last only until Q4 2026. The main risk is the ongoing financial losses, with a net income of -$2.97 million in Q2 2026, which raises concerns about long-term viability.